282 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28337319	28	Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization.	Universit£
27914947	11	Synthesis and binding monitoring of a new nanomolar PAMAM-based matrix metalloproteinases inhibitor (MMPIs).	University Of Florence
27825552	152	Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.	Takeda Pharmaceutical
27452283	241	Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.	Jadavpur University
27038494	18	Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.	Fudan University
27039251	66	Design, synthesis and anti-HIV-1 evaluation of hydrazide-based peptidomimetics as selective gelatinase inhibitors.	Shandong University
26871660	68	Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.	San Raffaele Scientific Institute
26653735	81	Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.	Pfizer
26753813	22	Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.	University Of Minnesota
26638045	58	Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.	Uit The Arctic University Of Norway
26346367	77	Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.	Nanjing University
26386821	15	Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.	Shandong University
26263024	47	N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.	Universit£
26192023	71	SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.	Florida Atlantic University
25264600	64	Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.	Takeda Pharmaceutical
25921268	36	New matrix metalloproteinase inhibitors based on¿-fluorinateda-aminocarboxylic anda-aminohydroxamic acids.	Westf£Lische Wilhelms-Universit£T M£Nster
25438884	11	A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹8F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging.	University Medical Center Groningen
25415648	63	Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.	Eli Lilly
25265401	38	Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.	Universidad Ceu San Pablo
25192810	66	Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.	Takeda Pharmaceutical
24813742	98	Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors.	Universit£
24755524	60	Design, synthesis and preliminary evaluation ofa-sulfonyl¿-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.	Shandong University
24028490	46	O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.	University Of Notre Dame
23453070	42	A series of thiazole derivatives bearing thiazolidin-4-one as non-competitive ADAMTS-5 (aggrecanase-2) inhibitors.	Asahi Kasei Pharma
23376997	53	Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.	Universit£
23375794	220	Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.	Nanjing University Of Chinese Medicine
23353736	41	Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).	Second Military Medical University
23287054	46	Sulphonamides: Deserving class as MMP inhibitors?	Indian Institute Of Technology (Bhu)
23458498	24	Synthesis and preliminary evaluation in tumor bearing mice of new (18)F-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography.	Universit£
23246356	52	MMP inhibition by barbiturate homodimers.	Trinity College
17275314	701	Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.	Pomona College
21669521	44	Selective non zinc binding inhibitors of MMP13.	Astrazeneca
23134659	74	Design and synthesis of procollagen C-proteinase inhibitors.	Fibrogen
24900417	59	Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.	TBA
22894736	99	Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment.	The Hebrew University Of Jerusalem
21780776	40	Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.	Wroclaw University Of Technology
21413800	56	A one-pot synthesis and biological activity of ageladine A and analogues.	Macquarie University
23149299	50	Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.	Universit£
22967811	62	Design, synthesis and evaluation of novel metalloproteinase inhibitors based on L-tyrosine scaffold.	Tianjin Medical University
22540974	67	A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.	University Hospital M£Nster
22248361	24	Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.	Trinity College
22737278	44	Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.	TBA
22658537	76	Natural products as a gold mine for selective matrix metalloproteinases inhibitors.	East China University Of Science And Technology
22175799	22	Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.	Alantos Pharmaceuticals
22607877	38	Design, synthesis and biological evaluation of novel amino acid ureido derivatives as aminopeptidase N/CD13 inhibitors.	Shandong University
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University Of Florida
19635666	119	Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.	Incyte
19339187	49	Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part II).	Shandong University
19329328	42	Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part I).	Shandong University
19095454	63	Current perspective of TACE inhibitors: a review.	The M. S. University Of Baroda
17981034	51	1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.	Johnson & Johnson Pharmaceutical Research And Development
18053726	364	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.	Johnson & Johnson Pharmaceutical Research & Development
17980583	46	Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).	Johnson & Johnson Pharmaceutical Research And Development
18086526	85	beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.	Johnson & Johnson Pharmaceutical Research And Development
18257543	16	Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.	The Hebrew University Of Jerusalem
18251495	69	Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
18061445	103	Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).	Bristol-Myers Squibb Research And Development
18029173	316	Synthesis and evaluation of novel heterocyclic MMP inhibitors.	North Dakota State University
17956082	86	Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.	University Hospital Of The Westf£Lische Wilhelms-Universit£T M£Nster
17127067	21	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.	Instituto Superior T£Cnico
17276072	95	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.	Universit£
15857146	30	C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.	University Hospital Of The Westf£Lische Wilhelms-Universit£T
15713379	40	N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.	Universit£
15582436	7	N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.	Sejong University
15139760	110	Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.	The Hebrew University Of Jerusalem
12930146	170	Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.	Institut De Recherches Servier
12773042	195	Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.	Wyeth Research
11472217	157	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.	Dupont Pharmaceuticals
11472202	143	Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.	TBA
10669559	180	Protease inhibitors: current status and future prospects.	University Of Queensland
10649971	180	Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.	Parke-Davis Pharmaceutical Research
10579818	162	Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.	Procter And Gamble Pharmaceuticals
9888835	42	Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.	Procter And Gamble Pharmaceuticals
1322986	13	Inhibition of collagenase by aranciamycin and aranciamycin derivatives.	Technical University Of Denmark
14980648	16	New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.	Universit£
15177439	96	Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.	Pfizer
12824028	75	Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3.	Pfizer
11327577	86	Heterocycle-based MMP inhibitors with P2' substituents.	Procter And Gamble Pharmaceuticals
11591510	57	alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.	Pfizer
11378378	34	Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.	Celltech-Chiroscience
11133099	43	Synthesis and activity of selective MMP inhibitors with an aryl backbone.	Pharmacia
10450979	4	Synthesis of an array of potential matrix metalloproteinase inhibitors using a sequence of polymer-supported reagents.	University Of Cambridge
10397503	40	Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.	Universit£
22386984	67	In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.	Colosseum Combinatorial Chemistry Centre For Technology (C4T Scarl)
22175825	19	Potent inhibitors of LpxC for the treatment of Gram-negative infections.	Pfizer
22118188	50	A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.	University Hospital M£Nster
22153941	140	Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.	Astrazeneca
22017539	75	Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.	Boehringer Ingelheim Pharmaceuticals
22017477	35	Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.	Instituto Superior T£Cnico
22153340	37	Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD).	Pfizer
22082667	67	Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.	Microbiotix
22088955	33	Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.	Universit£
21937229	82	Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.	Novartis Institutes For Biomedical Research
21925881	60	Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.	Johnson & Johnson Pharmaceutical Research & Development
21866961	28	Selective water-soluble gelatinase inhibitor prodrugs.	University Of Notre Dame
21911297	40	Design, synthesis and biological evaluation of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as aminopeptidase N/CD13 inhibitors.	Shandong University
21802307	64	Novel aminopeptidase N (APN/CD13) inhibitors derived from chloramphenicol amine.	Shandong University
21764590	98	N-substituted homopiperazine barbiturates as gelatinase inhibitors.	Trinity College
20726512	282	Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.	Pfizer
21514700	56	Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.	Universit£
21536437	219	Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.	Astrazeneca
20638281	56	Structure and activity relationships of tartrate-based TACE inhibitors.	Merck Research Laboratories
21507637	102	MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.	Pfizer
21493063	67	MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.	Pfizer
21458257	87	2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.	Merck Research Laboratories
21300546	129	The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.	Astrazeneca
21189019	22	Identifying chelators for metalloprotein inhibitors using a fragment-based approach.	University Of California
24900296	38	Sulfonate-Containing Thiiranes as Selective Gelatinase Inhibitors	TBA
20970895	4	2-Azetidinone--a new profile of various pharmacological activities.	Barkatullah University
21106451	39	Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.	Merck Research Laboratories
20637634	48	Novel aminopeptidase N (APN/CD13) inhibitors derived from 3-phenylalanyl-N'-substituted-2,6-piperidinedione.	Shandong University
20529685	70	MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.	Pfizer
20529684	112	Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.	Pfizer
20180536	128	Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.	Universit£
20172725	49	Discovery and SAR of hydantoin TACE inhibitors.	Merck Research Laboratories
20053563	10	Identification of potential and selective collagenase, gelatinase inhibitors from Crataegus pinnatifida.	Wonkwang University Sanbon Medical Center
20022498	71	The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.	Schering-Plough Research Institute
19969464	56	Design, synthesis and primary activity assay of bi- or tri-peptide analogues with the scaffold l-arginine as amino-peptidase N/CD13 inhibitors.	Shandong University
20097082	20	Novel matrix metalloproteinase inhibitors derived from quinoxalinone scaffold (Part I).	Shandong University
20005097	58	Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
19948404	1	Synthesis and anticancer activities of ageladine A and structural analogs.	Beckman Research Institute At City Of Hope
19782572	62	Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13.	Shandong University
19703773	63	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.	Gsk Medicines Research Centre
19775099	184	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.	Universit£
19454370	52	Design, synthesis and primary activity evaluation of L-arginine derivatives as amino-peptidase N/CD13 inhibitors.	Shandong University
19625186	59	3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding.	Wyeth Research
19524436	27	Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group.	University Of Shizuoka And Global Coe Program
19725580	93	Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.	Wyeth Research
19606871	124	N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.	Universit£
18835710	69	Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.	Schering-Plough Research Institute
	2	Synthesis of conformationally constrained potential inhibitors of mammalian metalloproteinases	TBA
	97	Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocket	TBA
	30	Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimics	TBA
	30	Orally active inhibitors of stromelysin-1 (MMP-3)	TBA
	60	Inhibition of matrix metalloproteinases by P1 substituted N-carboxyalkyl dipeptides	TBA
	49	Phosphinic acid inhibitors of matrix metalloproteinases	TBA
	18	Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1'	TBA
	66	Inhibition of matrix metalloproteinases by N-carboxyalkyl dipeptides: Enhanced potency and selectivity with substituted P1′ homophenylalanines	TBA
	40	Novel indolactam-based inhibitors of matrix metalloproteinases	TBA
	60	Potent and selective inhibitors of gelatinase-A 2. carboxylic and phosphonic acid derivatives	TBA
	76	Potent and selective inhibitors of gelatinase-a 1. hydroxamic acid derivatives	TBA
19457660	90	Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.	Incyte
19410464	71	Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.	Wyeth Research
19329309	49	Synthesis and biological evaluation of ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides: a class of potent aggrecanase-1 inhibitors.	Wyeth Research
19261472	16	Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.	University Of California
19053764	101	Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.	Instituto Superior TéCnico
18996018	42	Novel 3-phenylpropane-1,2-diamine derivates as inhibitors of aminopeptidase N (APN).	Shandong University
18945617	50	Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.	Pfizer
18790648	317	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.	University Of Athens
18782669	90	Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.	Université
18718763	50	Synthesis of new sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.	Shandong University
18571419	24	Novel aminopeptidase N inhibitors derived from 1,3,4-thiadiazole scaffold.	Shandong University
18467109	21	Design, synthesis, and QSAR studies of novel lysine derives as amino-peptidase N/CD13 inhibitors.	Shandong University
18440232	38	Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.	Shandong University
18362041	59	Design, synthesis and preliminary evaluation of novel pyrrolidine derivatives as matrix metalloproteinase inhibitors.	Shandong University
17719700	39	Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.	Università
17623656	34	Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.	Pfizer
18083558	112	beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.	Johnson & Johnson Pharmaceutical Research And Development
18068976	132	Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.	Incyte
18036818	157	Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.	Incyte
18029177	57	A novel series of highly selective inhibitors of MMP-3.	Pfizer
17936631	25	Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.	Yonsei University
17591762	102	Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.	Pfizer
17583333	4	Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12.	Università
17576061	132	Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
17531482	67	Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors.	Wyeth Research
17512742	32	Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.	Université
17433673	44	Novel 3-galloylamido-N'-substituted-2,6-piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors.	Shandong University
17428670	1	Inhibitory effect of obovatal on the migration and invasion of HT1080 cells via the inhibition of MMP-2.	Korea Research Institute Of Bioscience And Biotechnology
17368021	55	Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
17276676	112	A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
17267227	12	Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases.	Clermont Auvergne University
17256836	84	Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.	Incyte
17188863	107	Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
17088065	106	alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.	Università
17064892	123	Identification of potent and selective TACE inhibitors via the S1 pocket.	Wyeth Research
17027261	153	Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
16723229	108	Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.	Wyeth Research
16632358	68	Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.	Johnson & Johnson Pharmaceutical Research And Development
16516466	175	Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16473009	23	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16420030	38	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.	Chinese Academy Of Sciences
16392792	29	Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.	Aventis Pharma Deutschland
16289878	35	Conversion of potent MMP inhibitors into selective TACE inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16242329	12	N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8.	Università
16153831	87	Synthesis and SAR of highly selective MMP-13 inhibitors.	Wyeth Research
16005220	52	Identification of potent and selective MMP-13 inhibitors.	Wyeth Research
16002291	24	Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.	Pfizer
15953722	56	Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.	Pfizer
15908214	95	Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.	Bristol-Myers Squibb Pharmaceutical Research Institute
15837315	13	A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.	Università
15780611	74	Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.	Pfizer
15686921	55	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).	Pharmaceutical Research Institute
15357971	228	Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
15341955	52	Synthesis and evaluation of novel oxazoline MMP inhibitors.	North Dakota State University
15324896	71	3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.	Pfizer
15163188	12	A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics simulations.	University Of California San Francisco
15125955	84	Reverse hydroxamate-based selective TACE inhibitors.	Kaken Pharmaceutical
14711305	26	Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.	University Of Athens
14684295	109	Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.	Chinese Academy Of Sciences
14643313	132	Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.	Bristol-Myers Squibb Pharmaceutical Research Institute
14643312	39	Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.	Bristol-Myers Squibb Pharmaceutical Research Institute
14611841	10	MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3.	Umr/Cnrs 6013
12877590	28	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.	Pfizer
12877587	6	Development of a water-soluble matrix metalloproteinase inhibitor as an intra-arterial infusion drug for prevention of restenosis after angioplasty.	National Cardiovascular Center Research Institute
12798337	6	Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.	Indiana University School Of Medicine
12781190	113	Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
12729664	14	Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives.	Université
12723945	167	Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
12408705	73	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.	Bristol-Myers Squibb
11754593	148	Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.	Abbott Laboratories
11738583	45	Potent P1' biphenylmethyl substituted aggrecanase inhibitors.	Bristol-Myers Squibb Pharma
11677124	67	Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.	Abbott Laboratories
11585440	76	Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.	Dupont Pharmaceuticals
11585439	44	Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.	Dupont Pharmaceuticals
11563922	147	Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.	UniversitäT Bielefeld
11551755	18	Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor.	British Biotech Pharmaceuticals
11543676	45	Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.	Université
11543675	104	N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.	Université
11454461	111	The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.	Procter And Gamble Pharmaceuticals
11428927	117	A new concept for multidimensional selection of ligand conformations (MultiSelect) and multidimensional scoring (MultiScore) of protein-ligand binding affinities.	The Royal Danish School Of Pharmacy
11412980	48	Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.	Abbott Laboratories
11412979	67	Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.	Abbott Laboratories
11354379	37	Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.	Pfizer
11327602	58	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.	Roche Research Center
11297453	173	Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines.	Procter And Gamble Pharmaceuticals
11266157	12	Chemoenzymatic synthesis of functionalized cyclohexylglycines and alpha-methylcyclohexylglycines via Kazmaier-Claisen rearrangement.	University Of Florida
11229774	40	Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).	Pfizer
11229773	73	Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.	Pfizer
11212095	65	General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.	Institut De Recherches Servier
11150165	228	Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.	Procter And Gamble Pharmaceuticals
10937713	186	Solid-phase synthesis of an arylsulfone hydroxamate library.	Rhone-Poulenc Rorer
10882354	19	Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold.	Pfizer
10794702	340	Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.	Università
10639284	119	Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold.	University Of Florida
10522712	109	The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.	British Biotech Pharmaceuticals
10522699	37	Design, combinatorial chemical synthesis and in vitro characterization of novel urea based gelatinase inhibitors.	University Of Wisconsin-Madison
10411481	144	Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.	Cea
10346925	40	Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.	Shionogi
10052961	24	Dual inhibition of phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid template.	RhôNe-Poulenc Rorer
10021913	42	Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket.	Pfizer
9873712	109	Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.	Abbott Laboratories
9873491	56	The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.	Abbott Laboratories
9873367	39	Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution.	Abbott Laboratories
9599226	25	Macrocyclic amino carboxylates as selective MMP-8 inhibitors.	Dupont Pharmaceuticals
9548812	67	Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.	Kanebo
9484512	130	Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.	Shionogi
9457244	189	Matrix metalloproteinase inhibitors: a structure-activity study.	Glycomed
9191969	31	Dual inhibition of human leukocyte elastase and lipid peroxidation: in vitro and in vivo activities of azabicyclo[2.2.2]octane and perhydroindole derivatives.	Institut De Recherche Servier
9083493	95	Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.	Merck Research Laboratories
8277511	57	Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides.	Merck Research Laboratories
8064799	16	Cyclic peptides with a phosphinic bond as potent inhibitors of a zinc bacterial collagenase.	University Of Athens
21524149	13	Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands.	Suven Life Sciences
9353361	3	[3H]RY 80: A high-affinity, selective ligand for gamma-aminobutyric acidA receptors containing alpha-5 subunits.	National Institute Of Diabetes And Digestive And Kidney Diseases
8524985	69	D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs.	Case Western Reserve University
7680751	48	Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.	National Institute Of Neurological Disorders And Stroke
7518496	9	Cloning and expression of a 5-hydroxytryptamine7 receptor positively coupled to adenylyl cyclase.	Syntex Discovery Research
7515823	54	Actions of phenylglycine analogs at subtypes of the metabotropic glutamate receptor family.	Novo Nordisk
7509389	8	Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.	Fujisawa Pharmaceutical
19695884	156	Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides.	Vernalis (R&D)
19462975	18	Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.	Chemical Genomics Centre Of The Max Planck Society
17034127	45	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.	University Of Newcastle Upon Tyne
19345579	14	Synthesis and PKCtheta inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitriles.	Wyeth Research
19267461	53	Novel tricyclic inhibitors of IkappaB kinase.	Bristol-Myers Squibb